Welcome to our dedicated page for GREY MATTERS HEALTH INC, news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on GREY MATTERS HEALTH INC, stock.
Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Algernon Pharmaceuticals has announced promising topline data from its Phase 2 proof of concept study of NP-120 (Ifenprodil) as a treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough. The study showed 65% of patients achieved stable or improved forced vital capacity (FVC) compared to an expected placebo effect of 40% (p=0.0225). Additionally, 30% of subjects demonstrated a significant reduction in cough frequency. The company plans to file a pre-IND application for a Phase 2b study with the FDA, indicating a potential new treatment pathway for IPF patients.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced progress in its chronic kidney disease (CKD) research program using Repirinast, previously an asthma drug. In pre-clinical tests, Repirinast significantly reduced kidney fibrosis by 50%. The company is also exploring its use for acute interstitial nephritis. Manufacturing is underway, with a toxicology study planned post-synthesis, followed by a Phase 1 study set for Q4 2022. The global CKD drug market is projected to reach $15.8 billion by 2024, reflecting a substantial opportunity for Algernon's research endeavors.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) announced an update on its Phase 1 clinical study of AP-188 (DMT), a psychedelic compound. The Company is finalizing the intravenous formulation needed for the study, set to begin in September 2022, with the Centre for Human Drug Research in the Netherlands. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of DMT through prolonged infusion. The findings will inform future studies on DMT's potential in treating ischemic stroke and rehabilitation.
Algernon Pharmaceuticals has filed patent applications for novel salt forms of N,N-dimethyltryptamine (DMT), specifically nicotinate and pamoate, which may enhance DMT's efficacy and stability as a potential stroke treatment. Binding studies show these salts have similar receptor interactions compared to the traditional fumarate form. Additionally, pamoate exhibited neuroprotective effects in mouse models, and nicotinate showed improvements in neuroplasticity markers in rats. The company aims to solidify its intellectual property position around DMT as part of its drug repurposing strategy.
Algernon Pharmaceuticals has received a patent from the Canadian Intellectual Property Office for its treatment of interstitial lung disease using NP-120 (Ifenprodil), valid until 2038. The patent covers compositions and methods for treating idiopathic pulmonary fibrosis (IPF). Algernon is also pursuing active patent applications for Ifenprodil in the U.S., Europe, China, and Japan. The company is conducting a Phase 2 human trial for Ifenprodil's safety and efficacy in IPF patients, with topline data expected in July 2022.
Algernon Pharmaceuticals announced that patients in its Phase 2 study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis and chronic cough in Australia and New Zealand have requested ongoing access to the drug beyond the study period. The company is assisting these clinical sites in obtaining additional supplies via the Australian Government's Special Access Scheme. Topline data from the study is expected in July 2022. However, Algernon clarifies that it does not claim Ifenprodil can cure or treat these conditions at this time.
Algernon Pharmaceuticals Inc. has announced the database lock for its Phase 2 proof-of-concept study of NP-120 (Ifenprodil) targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. The trial, which began in 2020 and enrolled 20 patients, aims to assess Ifenprodil's safety and efficacy. Topline data is expected in July 2022, with primary endpoints focusing on lung function and cough reduction. The study includes subgroup analysis based on cough counts and serum biomarkers of fibrosis.
Algernon Pharmaceuticals has announced the completion of patient treatment in its Phase 2 proof-of-concept study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. Topline data is expected in July 2022. The trial enrolled 20 patients to assess Ifenprodil's safety and efficacy, focusing on lung function and cough reduction. The company aims to provide insights into the drug’s unique mechanism against current treatments, highlighting a pressing need for new options in managing IPF, which has a high mortality rate within 3-4 years.
Algernon Pharmaceuticals has announced promising results from a preclinical study of its lead compound, NP-251 (Repirinast), which demonstrated a significant 56% reduction in fibrosis related to chronic kidney disease (CKD) and non-alcoholic steatohepatitis (NASH) in animal models. The study showed statistical significance in the results, with strong implications for Repirinast’s potential as an anti-fibrotic treatment across various diseases. The company plans to advance Repirinast into a Phase 1 clinical trial, supported by a well-established safety history in the Japanese market.
Algernon Pharmaceuticals announced a contract with Zhejiang Ausun Pharmaceutical to manufacture cGMP supply of its repurposed drug NP-251 (Repirinast). This drug, previously used for asthma in Japan, showed a 50% reduction in kidney fibrosis in preclinical trials. The company initiated a new CKD research program, aiming for human trials following a bridging toxicity study. Global CKD drug market expected to grow from $11.5 billion in 2015 to $15.8 billion by 2024. Algernon plans trials in Australia and the U.S., leveraging tax credits for research costs.